Dorzolamide/Latanoprost

多佐胺/拉坦前列素

Report date: 2022/07/19 16:22:54

Base Information

Drug NameDorzolamide/Latanoprost
Drug Alias Name多佐胺+拉坦前列素Latanoprost/Dorzolamide拉坦前列素+盐酸多佐胺Dorzolamide+Latanoprost拉坦前列素/盐酸多佐胺 +[9] 
ClassificationSmall molecules
Mechanisms of ActionProstanoid FP receptor agonistsCarbonic anhydrases inhibitors
TargetsProstanoid FP receptorCarbonic anhydrases
Therapy Area/IndicationsGlaucoma, Open-AngleOcular Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsYes LatanoprostDorzolamide Hydrochloride
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAlleanza Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlleanza Pharmaceuticals IncChong Kun Dang Pharmaceutical Corp
Active IndicationsN/A
Inactive IndicationsGlaucoma, Open-AngleOcular Hypertension

Other Information

ATC CodeN/A
Related LinksN/A